By Professor Sean Emery

Journal articles

Birch C; Middleton T; Hales GP; Cooper DA; Law MG; Crowe S; Hoy JF; Emery S, 2003, 'Limited evolution of HIV antiretroviral drug resistance-associated mutations during the performance of drug resistance testing', Journal of Acquired Immune Deficiency Syndrome, 32, pp. 57 - 61

Law MG; Emery S, 2003, 'Selective exclusion of treatment arms in multi-arm randomized clinical trials', Statistics in Medicine, 22, pp. 19 - 30

Pettit CM; Garland JE; Etukudo NR; Assiongbon KA; Emery SB; Roy D, 2002, 'Electrodeposition of indium on molybdenum studied with optical second harmonic generation and electrochemical impedance spectroscopy', APPLIED SURFACE SCIENCE, 202, pp. 33 - 46, http://dx.doi.org/10.1016/S0169-4332(02)00798-5

Panteleeff DD; Emery S; Richardson BA; Rousseau C; Benki S; Bodrug S; Kreiss JK; Overbaugh J, 2002, 'Validation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay with genital swabs and breast milk samples', JOURNAL OF CLINICAL MICROBIOLOGY, 40, pp. 3929 - 3937, http://dx.doi.org/10.1128/JCM.40.11.3929-3937.2002

Garland JE; Assiongbon KA; Pettit CM; Emery SB; Roy D, 2002, 'Kinetic analysis of electrosorption using fast Fourier transform electrochemical impedance spectroscopy:: underpotential deposition of Bi³⁺ in the presence of coadsorbing ClO₄^- on gold', ELECTROCHIMICA ACTA, 47, pp. 4113 - 4124, http://dx.doi.org/10.1016/S0013-4686(02)00437-1

French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D; investigators* OBOO2, 2002, 'Randomized, open-Label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: The OzCombo 2 study', HIV Research & Clinical Practice, 3, pp. 177 - 185, http://dx.doi.org/10.1310/hct.2002.3.3.001

Emery S; Birch C; Crowe S; Hoy J; Workman C; Kelleher T; McKenna P; Cooper D; Lincoln D; Hales G; Law M, 2002, 'CREST - A randomised comparison of two resistance test platforms: genotype and genotype plus VirtualPhenotype (TM): interim results', ANTIVIRAL THERAPY, 7, pp. S152 - S152, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000177401300141&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Emery S; Cooper DA, 2002, 'HIV medicine', Medical Journal of Australia, 176, pp. 21 - 21

French MA; Amin J; Roth N; Law MG; Emery S; Drummond F, 2002, 'Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 infection: The OzCombo 2 Study', HIV Clinical Trials, 3, pp. 177 - 185

McNay LA; Tavel JA; Oseekey K; McDermott CM; Mollerup D; Bebchuk JD, 2002, 'Regulatory approvals in a large multinational clinical trial: the ESPRIT experience', CONTROLLED CLINICAL TRIALS, 23, pp. 59 - 66, http://dx.doi.org/10.1016/S0197-2456(01)00183-0

Emery S; Abrams D; Cooper DA; Darbyshire JH; Lane HC; Lundgren JD; Neaton JD, 2002, 'The evaluation of subcutaneous proleukin® (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials', Control Clin Trials, 23, pp. 198 - 220

Pett SL; Emery S, 2001, 'Immunomodulators as adjunctive therapy for HIV-1 infection', Journal of Clinical Virology, 22, pp. 289 - 295, http://dx.doi.org/10.1016/S1386-6532(01)00201-3

Tavel JA; Fosdick L, 2001, 'Closeout of four phase II Vanguard trials and patient rollover into a large international phase III HIV clinical endpoint trial', Controlled Clinical Trials, 22, pp. 42 - 48, http://dx.doi.org/10.1016/S0197-2456(00)00114-8

Emery S; Lane HC; Neaton JD, 2001, 'Interleukin-2 in clinical trials: Other factors to be considered - Reply', JOURNAL OF INFECTIOUS DISEASES, 183, pp. 680 - 680, http://dx.doi.org/10.1086/318546

Nannini EC, 2001, 'Interleukin-2 in clinical trials: Other factors to be considered (multiple letters)', Journal of Infectious Diseases, 183, pp. 679 - 680, http://dx.doi.org/10.1086/318544

Babiker AG; Darbyshire JH; Cooper DA; Hooker MH; Withnall R; Yeni P; Angarano G; Antunes F; Churchill D; Conway B; Flepp M; Lelekis M; Gatell J; Girard PM; Hemmer R; Lundgren J; Mijch A; Mulcahy F; Ristola M; Salzberger B; Sandström E; Staszewski S; Weber J; De Wit S; Aboulker JP; Emery S; Floridia M; Gartland M; Manion D; Popescu M; Schnittman S; Stek M; Verbiest W; Flandre P; Law M; Schade-Brittinger C; Walker S; Bucciardini R; Boukli N; Carey D; Gargalianos P; Mollerup D; Brun-Vezinet F; Loveday C; Seligmann M, 2001, 'An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: Design, rationale, and methods of the initio trial', Controlled Clinical Trials, 22, pp. 160 - 175, http://dx.doi.org/10.1016/S0197-2456(00)00123-9

Emery S; Bodrug S; Richardson BA; Giachetti C; Bott MA; Panteleeff D; Jagodzinski LL; Michael NL; Nduati R; Bwayo J; Kreiss JK; Overbaugh J, 2000, 'Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya', JOURNAL OF CLINICAL MICROBIOLOGY, 38, pp. 2688 - 2695, http://dx.doi.org/10.1128/JCM.38.7.2688-2695.2000

Losso MH; Belloso WH; Emery S, 2000, 'A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4(+) cell counts >= 350/mm(3) (vol 181, pg 1614, 2000)', JOURNAL OF INFECTIOUS DISEASES, 181, pp. 2122 - 2122, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000087923900051&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Losso MH; Belloso WH; Emery S, 2000, 'Erratum: A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts ≥350/mm3 (Journal of Infectious Diseases (May 2000) 181 (1614-1621))', Journal of Infectious Diseases, 181, pp. 2122, http://dx.doi.org/10.1086/315531

Carr AD; Chuah J; Hudson J; French MA; Hoy JF; Law MG; Sayer D; Emery S; Cooper DA; On BOTC, 2000, 'A randomised, open-label comparison of three highly active antiretroviral therapy regimes including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study', AIDS, 14, pp. 1171 - 1180

Ruxrungtham K; Suwanagool S; Tavel JA; Chuenyam M; Kroon E; Ubolyam S; Buranapraditkun S; Techasathit W; Li Y; Emery S; Davey RC; Fosdick L; Kunanusont C; Lane HC; Phanuphak P; And TVSG, 2000, 'A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand', AIDS, 14, pp. 2509 - 2513

Losso MH; Belloso WH; Emery S; Benetucci JA; Cahn PE; Lasala MC; Lopardo G; Salomon H; Saracco M; Nelson E; Law MG; Davey RC; Allende MC; Lane HC; And TVSG, 2000, 'A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts ? 350/mm³', Journal of Infectious Diseases, 181, pp. 1614 - 1621

Clezy KR; Emery S, 2000, 'Clinical trials of antiretroviral therapy in developing countries', Australian and New Zealand Journal of Medicine, pp. 3 - 4

Mills J; Carr AD; Smith DE; Emery S; Law MG; Grey PA; Cooper DA, 2000, 'Lipodystrophy following antiretroviral therapy of primary HIV infection (letter)', AIDS, 14, pp. 2406 - 2407

Emery S; Capra WB; Cooper DA; Mitsuyasu RT; Kovacs JA; Vig P; Smolskis M; Saravolatz LD; Lane HC; Fyfe G; Curtin PT; For TII, 2000, 'Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease', Journal of Infectious Diseases, 182, pp. 428 - 434

Cooper DA; Emery S, 1999, 'Latent reservoirs of HIV infection: Flushing with IL-2?', Nature Medicine, pp. 611 - 612

Kelleher AD; Roggensack M; Emery S; Carr AD; French MA; Cooper DA, 1998, 'Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens', Clinical and Experimental Immunology, 113, pp. 85 - 91

Carr AD; Emery S; Lloyd AR; Hoy JF; Garsia R; French MA; Stewart GA; Fyfe G; Cooper DA, 1998, 'Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, milticenter study', Journal of Infectious Diseases, 178, pp. 992 - 999, http://jid.oxfordjournals.org/content/178/4/992.full.pdf+html

Cooper DA; Emery S, 1998, 'Therapeutic strategies for HIV infection - time to think hard. (Editorial)', New England Journal of Medicine, pp. 1319 - 1321

Emery S; Cooper DA, 1997, 'Drug companies have a duty to continue treatment', British Medical Journal: Clinical Research, pp. 889 - 889

Emery S; Lane HC, 1997, 'Immune reconstitution in HIV infection', Current Opinion in Immunology, pp. 568 - 572

Kelleher S; Emery S; Cunningham PH; Duncombe CJ; Carr AD; Golding H; Forde S; Hudson J; Roggensack M; Forrest BD; Cooper DA, 1997, 'Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection', AIDS Research and Human Retroviruses, 13, pp. 29 - 32

Dax EM; Best SJ, 1996, 'If it's the virus why aren't we measuring it? [3]', Medical Journal of Australia, 165, pp. 119, http://dx.doi.org/10.5694/j.1326-5377.1996.tb124875.x

Emery S; Lane HC, 1996, 'Immune-based therapies in HIV infection: recent developments.', AIDS London England, 10 Suppl A, pp. S159 - S163, http://dx.doi.org/10.1097/00002030-199601001-00022

Carr AD; Emery S; Kelleher AD; Law MG; Cooper DA, 1996, 'CD8+ lymphocyte responses to antiretroviral therapy of HIV infection', Journal of acquired immune deficiency syndrome and human retrovirology, 13, pp. 320 - 326

Emery S; Lane HC, 1996, 'Immune-based therapies in HIV infection', AIDS, 10, pp. S159 - 164, http://dx.doi.org/10.1097/00002030-199601001-00022

Schooley RT; Ramirez-Ronda C; Lange JM; Cooper DA; Lavelle J; Lefkowitz L; Moore MW; Larder BA; St Clair M; Mulder JW; Mckinnis R; Pennington KN; Harrigan PR; Kinghorn I; Steel H; Rooney J, 1996, 'Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy', Journal of Infectious Diseases, 173, pp. 1354 - 1366

Emery S; Cooper DA, 1995, 'Antiretro viral therapy of human immunodeficiency virus type‐1 (HIV‐1) infection', Australian and New Zealand Journal of Medicine, 25, pp. 344 - 349, http://dx.doi.org/10.1111/j.1445-5994.1995.tb01900.x

Emery S; Carr A; Cooper DA, 1995, 'If it's the virus, why aren't we measuring it?', Medical Journal of Australia, 163, pp. 508 - 509, http://dx.doi.org/10.5694/j.1326-5377.1995.tb124712.x

Cooper DA; Gatell JM; Kroon S; Clumeck N; Millard J; Goebel FD; Bruun JN; Stingl G; Melville RL; Gonzalez-Lahoz J; Stevens JW; Fiddian AP, 1993, 'Zidovudine in Persons with Asymptomatic HIV Infection and CD4+ Cell Counts Greater than 400 per Cubic Millimeter', New England Journal of Medicine, 329, pp. 297 - 303, http://dx.doi.org/10.1056/NEJM199307293290501

Slater TF; Cheeseman KH; Benedetto C; Collins M; Emery S; Maddix SP; Nodes JT; Proudfoot K; Burton GW; Ingold KU, 1990, 'Studies on the hyperplasia ('regeneration') of the rat liver following partial hepatectomy. Changes in lipid peroxidation and general biochemical aspects', Biochemical Journal, 265, pp. 51 - 59, http://dx.doi.org/10.1042/bj2650051

Cheeseman KH; Emery S; Maddix SP; Slater TF; Burton GW; Ingold KU, 1988, 'Studies on lipid peroxidation in normal and tumour tissues. The Yoshida rat liver tumour', Biochemical Journal, 250, pp. 247 - 252, http://dx.doi.org/10.1042/bj2500247

Cheeseman KH; Davies MJ; Emery S; Maddix SP; Slater TF, 1987, 'Effects of αtocopherol on carbon tetrachloride metabolism in rat liver microsomes', Free Radical Research, 3, pp. 325 - 330, http://dx.doi.org/10.3109/10715768709069800

Emery S; Oldham HG; Norman SJ; Chenery RJ, 1985, 'The effect of cimetidine and ranitidine on paracetamol glucuronidation and sulphation in cultured rat hepatocytes', Biochemical Pharmacology, 34, pp. 1415 - 1421, http://dx.doi.org/10.1016/0006-2952(85)90678-1

Conference Papers

Kunisaki KM; Niewoehner DE; Collins G; Aagaard B; Atako NB; Bakowska E; Clarke A; Corbelli GM; Ekong E; Emery S; Finley EB; Florence E; Infante RM; Kityo CM; Madero JS; Nixon DE; Tedaldi E; Vestbo J; Wood R; Connett JE, 2018, 'Pulmonary Effects of Immediate Versus Deferred Antriretroviral Treatment Initiation: Final Follow-Up Results from the Randomized Strategic Timing of Antiretroviral Treatment (START) Pulmonary Substudy', in AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, AMER THORACIC SOC, CA, San Diego, presented at International Conference of the American-Thoracic-Society, CA, San Diego, 18 May 2018 - 23 May 2018

Belonohy E; Baker A; Balshaw N; Bernardo J; Blatchford P; Camp P; Cane J; Ciric D; Craven R; Emery S; Felton R; Gee S; Graham B; Haupt T; Hotchin S; Jones G; Keeling D; Jones T; Keenan T; Knipe S; McAdams R; Rimini F; Sips A; Warren R; Zastrow K-D, 2016, 'Technical rehearsal of tritium operation at JET', in FUSION ENGINEERING AND DESIGN, ELSEVIER SCIENCE SA, CZECH REPUBLIC, Prague, pp. 196 - 200, presented at 29th Symposium on Fusion Technology (SOFT), CZECH REPUBLIC, Prague, 05 September 2016 - 09 September 2016, http://dx.doi.org/10.1016/j.fusengdes.2017.01.056

Madhavi V; Wines B; Emery S; Amin J; Kelleher A; Hogarth M; Stratov I; Kent S, 2016, '"HIV-1 controllers" - what's their secret?', in EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY-BLACKWELL, AUSTRALIA, Melbourne, pp. 74 - 74, presented at International Congress of Immunology (ICI), AUSTRALIA, Melbourne, 21 August 2016 - 26 August 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000383610400148&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wines BD; Vanderven HA; Esparon S; Madhavi V; Center RJ; Kristensen AB; Gonelli CA; Poumbourios A; Parsons M; Emery S; Kelleher A; Purcell DFJ; Kent SJ; Hogarth PM, 2016, 'Fc gamma R ectodomain probes measure anti-viral IgG effector function', in EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY-BLACKWELL, AUSTRALIA, Melbourne, pp. 1256 - 1257, presented at International Congress of Immunology (ICI), AUSTRALIA, Melbourne, 21 August 2016 - 26 August 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000391563600040&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Rodger A; Lampe F; Burman W; Gruhlich A; Friedland G; El-Sadr W; Neaton J; Emery S; Corbelli G; Molina JM; Orkin C; Gatell J; Gerstoft J; Ruxrungtham K; de Souza MB; Phillips A, 2016, 'Assessment of the impact of early ART on sexual behaviour in INSIGHT strategic timing of antiretroviral treatment (START) trial', in JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, JOHN WILEY & SONS LTD, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000395394300243&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Achhra AC; Phillips AN; Emery S; MacArthur RD; Furrer H; De Wit S; Losso MH; Law MG, 2015, 'PRE-THERAPY INFLAMMATION/COAGULATION ACTIVATION AND LONG-TERM CD4 RESPONSE TO ANTIRETROVIRAL THERAPY', in SEXUALLY TRANSMITTED INFECTIONS, BMJ PUBLISHING GROUP, pp. A73 - A73, http://dx.doi.org/10.1136/sextrans-2015-052270.195

Back to profile page